Nadler Financial Group Inc. Purchases 65 Shares of Eli Lilly and Company (NYSE:LLY)

Nadler Financial Group Inc. boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,427 shares of the company’s stock after purchasing an additional 65 shares during the quarter. Nadler Financial Group Inc.’s holdings in Eli Lilly and Company were worth $1,415,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after acquiring an additional 7,330,815 shares during the period. Sapient Capital LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at $435,736,000. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its stake in Eli Lilly and Company by 24.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after buying an additional 645,473 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Finally, Bank of America raised their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

LLY traded up $10.15 during trading on Friday, reaching $735.02. 870,862 shares of the company’s stock were exchanged, compared to its average volume of 3,006,560. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a market capitalization of $698.39 billion, a P/E ratio of 126.80, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company’s fifty day simple moving average is $762.75 and its 200-day simple moving average is $664.94. Eli Lilly and Company has a 1 year low of $380.77 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.09 EPS. As a group, research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.